Filing Details
- Accession Number:
- 0001062993-23-007221
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-03-17 18:37:22
- Reporting Period:
- 2023-03-15
- Accepted Time:
- 2023-03-17 18:37:22
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1177648 | Enanta Pharmaceuticals Inc | ENTA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1571212 | Sun Yat Or | C/O Enanta Pharmaceuticals, Inc. 500 Arsenal Street Watertown MA 02472 | Sr. Vp & Cso | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-03-15 | 13,925 | $14.00 | 388,627 | No | 4 | M | Direct | |
Common Stock | Disposition | 2023-03-15 | 269 | $43.92 | 388,358 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-03-15 | 13,656 | $44.46 | 374,702 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2023-03-15 | 13,925 | $0.00 | 13,925 | $14.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2023-03-21 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in November 2022.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.86 to $43.96, inclusive.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.02 to $45.00, inclusive.
- On March 21, 2013, the reporting person was granted an option to purchase 41,763 shares of common stock, half of which became exercisable upon the achievement of several clinical milestones during the four-year performance period after the date of grant.